<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042219</url>
  </required_header>
  <id_info>
    <org_study_id>Uniklinik RWTH Aachen</org_study_id>
    <nct_id>NCT05042219</nct_id>
  </id_info>
  <brief_title>Effects of Pulmonary Diseases and Their Treatment on Cardiac Function</brief_title>
  <official_title>The Relationship Between Pulmonary and Cardiac Dysfunction and the Cardiac Effects of Pulmonary Treatments: Cardiopulmonary MRI Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayham Daher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the bidirectional relationship between the lung and the right heart are well studied,&#xD;
      the cardiopulmonary interactions between the lung and the left heart are largely unresearched&#xD;
      and not well understood. However, in recent years, there is a growing evidence that partially&#xD;
      explains the bidirectional interaction between COPD and left heart. Systemic inflammation&#xD;
      with multiorgan involvement is thought to play a role in COPD as a systemic disease. Some&#xD;
      therapeutic approaches to COPD also appear to influence these cardiopulmonary interactions.&#xD;
      While understanding these interactions is very important for clinicians, scientific data are&#xD;
      scarce. Cardiac magnetic resonance imaging (cardiac MRI) is the gold standard for assessing&#xD;
      cardiac function and dimensions as well as myocardial inflammation. Despite this excellent&#xD;
      suitability of cardiac MRI for the assessment of cardiovascular function, only few studies&#xD;
      have investigated cardiac function and myocardial structure in patients with pulmonary&#xD;
      disease using cardiac MRI. Such a study is therefore very important for understanding the&#xD;
      effects of pulmonary disease and its management on the heart.&#xD;
&#xD;
      The objective is to determine cardiac function in patients with pulmonary disease and to&#xD;
      analyze the cardiovascular effects of the treatment of the pulmonary disease.&#xD;
&#xD;
      Specifically, the following will be studied:&#xD;
&#xD;
        -  Using cardiac MRI: Cardiac function and volumes and indications of myocardial fibrosis&#xD;
           and edema in patients with chronic pulmonary disease at the time of first diagnosis.&#xD;
&#xD;
        -  the vascular function of pulmonary arteries in these patients, also using cardiac MRI&#xD;
&#xD;
        -  the relationship between pulmonary function parameters and cardiac dysfunction to&#xD;
           identify patients at increased risk, if applicable.&#xD;
&#xD;
        -  Echocardiographic assessment of left heart including strain analysis.&#xD;
&#xD;
        -  the course of these cardiovascular parameters (using cardiac MRI and echocardiography)&#xD;
           3-6 months after initiation of guideline-based therapy for pulmonary disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>left-ventricular end-diastolic volume</measure>
    <time_frame>3 months</time_frame>
    <description>left-ventricular end-diastolic volume before and after therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary microvascular blood flow (physiological parameter: ml/min/100 ml Lung volume)</measure>
    <time_frame>3 months</time_frame>
    <description>Pulmonary microvascular blood flow (physiological parameter: ml/min/100 ml Lung volume) before and after therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of myocardial fibrosis or edema (pathophysiological parameter: yes/no)</measure>
    <time_frame>3 months</time_frame>
    <description>Presence of myocardial fibrosis or edema (pathophysiological parameter: yes/no) before and after therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular global longitudinal strain (physiological parameter)</measure>
    <time_frame>3 months</time_frame>
    <description>Left ventricular global longitudinal strain (physiological parameter) before and after therapy</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COPD</condition>
  <condition>Bronchial Asthma</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>COPD (ICS)</arm_group_label>
    <description>COPD before initiation of inhaled corticosteroid therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD (LTOT-NIV)</arm_group_label>
    <description>COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD (Roflumilast )</arm_group_label>
    <description>COPD before initiation of Roflumilast therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchial asthma (antibody)</arm_group_label>
    <description>Bronchial asthma before initiation of antibody therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchial asthma (ICS)</arm_group_label>
    <description>Bronchial asthma before initiation of inhaled corticosteroid therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary fibrosis</arm_group_label>
    <description>Pulmonary fibrosis before initiation of antifibrotic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter</description>
    <arm_group_label>Bronchial asthma (ICS)</arm_group_label>
    <arm_group_label>Bronchial asthma (antibody)</arm_group_label>
    <arm_group_label>COPD (ICS)</arm_group_label>
    <arm_group_label>COPD (LTOT-NIV)</arm_group_label>
    <arm_group_label>COPD (Roflumilast )</arm_group_label>
    <arm_group_label>Pulmonary fibrosis</arm_group_label>
    <other_name>Echocardiography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients with COPD group D and new prescription of ICS therapy.&#xD;
&#xD;
          -  Patients with COPD and new prescription of long-term O2 therapy or domiciliary&#xD;
             long-term non-invasive ventilation.&#xD;
&#xD;
          -  Patients with COPD and new prescription of Roflumilast therapy.&#xD;
&#xD;
          -  Patients with bronchial asthma and new prescription of antibody therapy.&#xD;
&#xD;
          -  Patients with bronchial asthma at initial diagnosis and new prescription of ICS&#xD;
             mono-therapy.&#xD;
&#xD;
          -  Patients with initial diagnosis of pulmonary fibrosis and new prescription of&#xD;
             antifibrotic therapy (nintedanib or pirfinidone).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic lung disease requiring treatment (COPD, asthma, or pulmonary&#xD;
             fibrosis).&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed consent to participate in the study will sign&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who are not fully capable of giving consent and understanding the nature,&#xD;
             significance and scope of the study.&#xD;
&#xD;
          -  Patients with contraindications to MRI examination (eg, pacemaker, severe&#xD;
             claustrophobia) or to contrast medium use (severe renal insufficiency or glomerular&#xD;
             filtration rate &lt;30 ml/min, known gadolinium contrast medium allergy)&#xD;
&#xD;
          -  Patients with atrial fibrillation or other significant cardiac arrhythmias that&#xD;
             interfere with cardiac MRI&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayham Daher, M.D.</last_name>
    <phone>+492418088763</phone>
    <email>adaher@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>RWTH Aachen University</investigator_affiliation>
    <investigator_full_name>Ayham Daher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

